Stock Traders Buy Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) was the target of unusually large options trading on Wednesday. Stock traders bought 23,134 call options on the company. This represents an increase of 432% compared to the typical volume of 4,347 call options.

Sangamo Therapeutics Price Performance

Shares of Sangamo Therapeutics stock opened at $0.92 on Friday. The business has a 50-day moving average of $1.12 and a 200-day moving average of $1.40. The company has a market capitalization of $192.75 million, a PE ratio of -1.23 and a beta of 1.49. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SGMO. StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a report on Monday, January 27th. Wells Fargo & Company lowered their price target on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Tuesday, December 31st. Barclays increased their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Finally, Jefferies Financial Group lowered their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, December 31st. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $5.17.

Institutional Trading of Sangamo Therapeutics

Several large investors have recently modified their holdings of the business. Point72 Asset Management L.P. acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at about $2,316,000. Geode Capital Management LLC grew its stake in shares of Sangamo Therapeutics by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company’s stock valued at $2,257,000 after acquiring an additional 73,540 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Sangamo Therapeutics during the fourth quarter worth about $1,744,000. Charles Schwab Investment Management Inc. lifted its position in shares of Sangamo Therapeutics by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company’s stock worth $1,162,000 after purchasing an additional 35,926 shares during the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Sangamo Therapeutics by 222.1% during the fourth quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after purchasing an additional 698,296 shares during the last quarter. 56.93% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.